Primary Site >> Biliary tract Cancer

Gene >> FGFR2

Journal: Hepatol Res. 2001 May 1;20(1):97-113.
Title: Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines.
Author: Ogasawara, S|Yano, H|Higaki, K|Takayama, A|Akiba, J|Shiota, K|Kojiro, M
PMID: 11282489
Journal: Anticancer Res. 2010 Oct;30(10):4115-21.
Title: Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer.
Author: Amano, Ryosuke|Yamada, Nobuya|Doi, Yosuke|Yashiro, Masakazu|Ohira, Masaichi|Miwa, Atsushi|Hirakawa, Kosei
PMID: 21036728
Journal: Hepatology. 2014 Apr;59(4):1427-34.
Title: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Author: Arai, Yasuhito|Totoki, Yasushi|Hosoda, Fumie|Shirota, Tomoki|Hama, Natsuko|Nakamura, Hiromi|Ojima, Hidenori|Furuta, Koh|Shimada, Kazuaki|Okusaka, Takuji|Kosuge, Tomoo|Shibata, Tatsuhiro
PMID: 24122810
Journal: PLoS Genet. 2014 Feb 13;10(2):e1004135.
Title: Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Author: Borad, Mitesh J|Champion, Mia D|Egan, Jan B|Liang, Winnie S|Fonseca, Rafael|Bryce, Alan H|McCullough, Ann E|Barrett, Michael T|Hunt, Katherine|Patel, Maitray D|Young, Scott W|Collins, Joseph M|Silva, Alvin C|Condjella, Rachel M|Block, Matthew|McWilliams,
PMID: 24550739
Journal: Oncologist. 2014 Mar;19(3):235-42.
Title: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Author: Ross, Jeffrey S|Wang, Kai|Gay, Laurie|Al-Rohil, Rami|Rand, Janne V|Jones, David M|Lee, Hwa J|Sheehan, Christine E|Otto, Geoff A|Palmer, Gary|Yelensky, Roman|Lipson, Doron|Morosini, Deborah|Hawryluk, Matthew|Catenacci, Daniel V T|Miller, Vincent A|Churi, C
PMID: 24563076
Journal: Hum Pathol. 2014 Aug;45(8):1630-8.
Title: Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Author: Graham, Rondell P|Barr Fritcher, Emily G|Pestova, Ekaterina|Schulz, John|Sitailo, Leonid A|Vasmatzis, George|Murphy, Stephen J|McWilliams, Robert R|Hart, Steven N|Halling, Kevin C|Roberts, Lewis R|Gores, Gregory J|Couch, Fergus J|Zhang, Lizhi|Borad, Mites
PMID: 24837095
Journal: Nat Commun. 2015 Jan 22;6:6087.
Title: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Author: Sia, Daniela|Losic, Bojan|Moeini, Agrin|Cabellos, Laia|Hao, Ke|Revill, Kate|Bonal, Dennis|Miltiadous, Oriana|Zhang, Zhongyang|Hoshida, Yujin|Cornella, Helena|Castillo-Martin, Mireia|Pinyol, Roser|Kasai, Yumi|Roayaie, Sasan|Thung, Swan N|Fuster, Josep|Schw
PMID: 25608663
Journal: J Gastroenterol Hepatol. 2015 Jul;30(7):1116-22.
Title: Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Author: Ang, Celina
PMID: 25678238
Journal: Curr Opin Gastroenterol. 2015 May;31(3):264-8.
Title: Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Author: Borad, Mitesh J|Gores, Gregory J|Roberts, Lewis R
PMID: 25763789
Journal: Nat Genet. 2015 Sep;47(9):1003-10.
Title: Genomic spectra of biliary tract cancer.
Author: Nakamura, Hiromi|Arai, Yasuhito|Totoki, Yasushi|Shirota, Tomoki|Elzawahry, Asmaa|Kato, Mamoru|Hama, Natsuko|Hosoda, Fumie|Urushidate, Tomoko|Ohashi, Shoko|Hiraoka, Nobuyoshi|Ojima, Hidenori|Shimada, Kazuaki|Okusaka, Takuji|Kosuge, Tomoo|Miyagawa, Shinichi
PMID: 26258846
Journal: J Gastrointest Oncol. 2016 Oct;7(5):797-803.
Title: Molecular profiling of biliary tract cancer: a target rich disease.
Author: Jain, Apurva|Javle, Milind
PMID: 27747093
Journal: Chin Clin Oncol. 2016 Oct;5(5):65.
Title: Systemic therapy for biliary cancers.
Author: Jordan, Emmet|Abou-Alfa, Ghassan K|Lowery, Maeve A
PMID: 27829278
Journal: J Gastrointest Oncol. 2016 Oct;7(5):789-796.
Title: The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Author: Rizvi, Sumera|Borad, Mitesh J
PMID: 27747092
Journal: PLoS One. 2016 Sep 14;11(9):e0162594.
Title: Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.
Author: Hall, Terence G|Yu, Yi|Eathiraj, Sudharshan|Wang, Yunxia|Savage, Ronald E|Lapierre, Jean-Marc|Schwartz, Brian|Abbadessa, Giovanni
PMID: 27627808
Journal: Cancer. 2016 Dec 15;122(24):3838-3847.
Title: Biliary cancer: Utility of next-generation sequencing for clinical management.
Author: Javle, Milind|Bekaii-Saab, Tanios|Jain, Apurva|Wang, Ying|Kelley, Robin Katie|Wang, Kai|Kang, Hyunseon C|Catenacci, Daniel|Ali, Siraj|Krishnan, Sunil|Ahn, Daniel|Bocobo, Andrea Grace|Zuo, Mingxin|Kaseb, Ahmed|Miller, Vincent|Stephens, Philip J|Meric-Berns
PMID: 27622582
Journal: Cancer Lett. 2016 Sep 28;380(1):163-73.
Title: Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
Author: Wang, Yu|Ding, Xiwei|Wang, Shaoqing|Moser, Catherine D|Shaleh, Hassan M|Mohamed, Essa A|Chaiteerakij, Roongruedee|Allotey, Loretta K|Chen, Gang|Miyabe, Katsuyuki|McNulty, Melissa S|Ndzengue, Albert|Barr Fritcher, Emily G|Knudson, Ryan A|Greipp, Patricia T
PMID: 27216979
Journal: Oncotarget. 2016 Jul 19;7(29):46750-46767.
Title: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Author: Chong, Dawn Q|Zhu, Andrew X
PMID: 27102149
Journal: J Clin Pathol. 2016 May;69(5):403-8.
Title: Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.
Author: Lee, Hwajeong|Wang, Kai|Johnson, Adrienne|Jones, David M|Ali, Siraj M|Elvin, Julia A|Yelensky, Roman|Lipson, Doron|Miller, Vincent A|Stephens, Philip J|Javle, Milind|Ross, Jeffrey S
PMID: 26500333
Journal: Clin Cancer Res. 2016 Jan 15;22(2):291-300.
Title: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
Author: Moeini, Agrin|Sia, Daniela|Bardeesy, Nabeel|Mazzaferro, Vincenzo|Llovet, Josep M
PMID: 26405193
Journal: Am J Surg Pathol. 2016 Aug;40(8):1021-30.
Title: Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma.
Author: Hayashi, Akimasa|Misumi, Kento|Shibahara, Junji|Arita, Junichi|Sakamoto, Yoshihiro|Hasegawa, Kiyoshi|Kokudo, Norihiro|Fukayama, Masashi
PMID: 27259014
Journal: Br J Cancer. 2017 Nov 21;117(11):1592-1599.
Title: A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
Author: Papadopoulos, K P|El-Rayes, B F|Tolcher, A W|Patnaik, A|Rasco, D W|Harvey, R D|LoRusso, P M|Sachdev, J C|Abbadessa, G|Savage, R E|Hall, T|Schwartz, B|Wang, Y|Kazakin, J|Shaib, W L
PMID: 28972963
Journal: J Gastrointest Oncol. 2017 Jun;8(3):430-440.
Title: Current biologics for treatment of biliary tract cancers.
Author: Zhao, Diana Y|Lim, Kian-Huat
PMID: 28736630
Journal: Therap Adv Gastroenterol. 2017 Jun;10(6):507-520.
Title: The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.
Author: Lee, Hwajeong|Ross, Jeffrey S
PMID: 28567120
Journal: Cancer Discov. 2017 Mar;7(3):248-249.
Title: Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.
Author: Smyth, Elizabeth C|Babina, Irina S|Turner, Nicholas C
PMID: 28264865
Journal: Gastroenterology. 2017 Mar;152(4):745-761.
Title: Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Author: Sia, Daniela|Villanueva, Augusto|Friedman, Scott L|Llovet, Josep M
PMID: 28043904
Journal: Cancer Discov. 2017 Mar;7(3):252-263.
Title: Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Author: Goyal, Lipika|Saha, Supriya K|Liu, Leah Y|Siravegna, Giulia|Leshchiner, Ignaty|Ahronian, Leanne G|Lennerz, Jochen K|Vu, Phuong|Deshpande, Vikram|Kambadakone, Avinash|Mussolin, Benedetta|Reyes, Stephanie|Henderson, Laura|Sun, Jiaoyuan Elisabeth|Van Sevente
PMID: 28034880
Journal: Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460.
Title: Targeting cholangiocarcinoma.
Author: Mertens, Joachim C|Rizvi, Sumera|Gores, Gregory J
PMID: 28844952
Journal: J Clin Oncol. 2018 Jan 20;36(3):276-282.
Title: Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Author: Javle, Milind|Lowery, Maeve|Shroff, Rachna T|Weiss, Karl Heinz|Springfeld, Christoph|Borad, Mitesh J|Ramanathan, Ramesh K|Goyal, Lipika|Sadeghi, Saeed|Macarulla, Teresa|El-Khoueiry, Anthony|Kelley, Robin Kate|Borbath, Ivan|Choo, Su Pin|Oh, Do-Youn|Philip,
PMID: 29182496
Journal: Future Oncol. 2018 Mar;14(6):553-566.
Title: Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
Author: DeLeon, Thomas T|Ahn, Daniel H|Bogenberger, James M|Anastasiadis, Panos Z|Arora, Mansi|Ramanathan, Ramesh K|Aqel, Bashar A|Vasmatzis, George|Truty, Mark J|Oklu, Rahmi|Bekaii-Saab, Tanios S|Borad, Mitesh J
PMID: 29460642
Journal: Hum Pathol. 2018 Jun;76:100-109.
Title: Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
Author: Pu, Xiao-Hong|Ye, Qing|Yang, Jun|Wu, Hong-Yan|Ding, Xi-Wei|Shi, Jiong|Mao, Liang|Fan, Xiang-Shan|Chen, Jun|Qiu, Yu-Dong|Huang, Qin
PMID: 29514108
Journal: Cancer Sci. 2018 May;109(5):1282-1291.
Title: Molecular genomic landscapes of hepatobiliary cancer.
Author: Shibata, Tatsuhiro|Arai, Yasuhito|Totoki, Yasushi
PMID: 29573058
Journal: Clin Cancer Res. 2018 Sep 1;24(17):4154-4161.
Title: Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Author: Lowery, Maeve A|Ptashkin, Ryan|Jordan, Emmet|Berger, Michael F|Zehir, Ahmet|Capanu, Marinela|Kemeny, Nancy E|O'Reilly, Eileen M|El-Dika, Imane|Jarnagin, William R|Harding, James J|D'Angelica, Michael I|Cercek, Andrea|Hechtman, Jaclyn F|Solit, David B|Schu
PMID: 29848569
Journal: Jpn J Clin Oncol. 2018 Aug 1;48(8):703-711.
Title: New developments in systemic therapy for advanced biliary tract cancer.
Author: Morizane, Chigusa|Ueno, Makoto|Ikeda, Masafumi|Okusaka, Takuji|Ishii, Hiroshi|Furuse, Junji
PMID: 29893894
Journal: Hepatology. 2018 Aug 1.
Title: HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma.
Author: Lamberti, Dante|Cristinziano, Giulia|Porru, Manuela|Leonetti, Carlo|Egan, Jan B|Shi, Chang-Xin|Buglioni, Simonetta|Amoreo, Carla A|Castellani, Loriana|Borad, Mitesh J|Alema, Stefano|Anastasi, Sergio|Segatto, Oreste
PMID: 30067876
Journal: Front Genet. 2018 Aug 15;9:309.
Title: Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.
Author: Shiao, Meng-Shin|Chiablaem, Khajeelak|Charoensawan, Varodom|Ngamphaiboon, Nuttapong|Jinawath, Natini
PMID: 30158952
Journal: J Cell Mol Med. 2018 Aug 30.
Title: Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling.
Author: Xu, Yun-Fei|Liu, Hong-Da|Liu, Zeng-Li|Pan, Chang|Yang, Xiao-Qing|Ning, Shang-Lei|Zhang, Zong-Li|Guo, Sen|Yu, Jin-Ming
PMID: 30160357